Home | Welcome to Contract Pharma   
Last Updated Friday, October 24 2014
Print

Financial Report: Charles River Laboratories



Published August 7, 2014
Charles River Laboratories

2Q Revenues: $341.2 million (+16%)

2Q Earnings: $35.3 million (+29%)

YTD Revenues: $640.5 million (+8%)

YTD Earnings: $67.5 million (+28%)

Comments: Revenue for the Research Models and Services (RMS) segment was $133.1 million in the quarter, up 3%. Discovery and Safety Assessment (DSA) revenue was $142.6 million, up 33% in quarter driven by the acquisition of Argenta and BioFocus, which contributed 22% to DSA revenue. Revenue for the Manufacturing segment was $65.4 million in the quarter, up 18% with growth across all businesses, including a double-digit growth rate for both the Endotoxin and Microbial Detection, and Biologics Testing Solutions businesses.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On